New treatments for the motor symptoms of Parkinson’s disease

References

• Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55(3):181-4
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord 2011;26(Suppl 3):S2-41
   PubMed Web of Science ®Google Scholar
• Warren Olanow C, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 2013;28(8):1064-71
   PubMed Web of Science ®Google Scholar
• Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 2008;23(Suppl 3):S580-4
   PubMed Web of Science ®Google Scholar
• Huot P, Johnston TH, Koprich JB, et al. The pharmacology of L-DOPA-induced dyskinesia in Parkinson’s disease. Pharmacol Rev 2013;65(1):171-222
   PubMed Web of Science ®Google Scholar
• Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001;2(8):577-88
   PubMed Web of Science ®Google Scholar
• Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 2005;20(8):919-31
   PubMed Web of Science ®Google Scholar
• Gauthier S, Amyot D. Sustained release antiparkinson agents: controlled release levodopa. Can J Neurol Sci 1992;19(1 Suppl):153-5
   PubMed Web of Science ®Google Scholar
• Zhou CQ, Lou JH, Zhang YP, et al. Long-acting versus standard non-ergot dopamine agonists in Parkinson’s disease: a meta-analysis of randomized controlled trials. CNS Neurosci Ther 2014;20(4):368-76
   PubMed Web of Science ®Google Scholar
• Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson’s disease. Drugs Aging 2004;21(11):687-709
   PubMed Web of Science ®Google Scholar
• Bartl J, Muller T, Grunblatt E, et al. Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. J Neural Transm 2014;121(4):379-83
   PubMed Web of Science ®Google Scholar
• Hirvonen J, Kailajarvi M, Haltia T, et al. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther 2009;85(5):506-12
   PubMed Web of Science ®Google Scholar
• Jankovic J, Berkovich E, Eyal E, Tolosa E. Symptomatic efficacy of rasagiline monotherapy in early Parkinson’s disease: post-hoc analyses from the ADAGIO trial. Parkinsonism Relat Disord 2014;20(6):640-3
   PubMed Web of Science ®Google Scholar
• Conn PJ, Battaglia G, Marino MJ, Nicoletti F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 2005;6(10):787-98
   PubMed Web of Science ®Google Scholar
• Duty S. Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson’s disease. CNS Drugs 2012;26(12):1017-32
   PubMed Web of Science ®Google Scholar
• Calabresi P, Giacomini P, Centonze D, Bernardi G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol 2000;47(4 Suppl 1):S60-8. discussion S68-69
   PubMed Web of Science ®Google Scholar
• Thomas A, Iacono D, Luciano AL, et al. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004;75(1):141-3
   PubMed Web of Science ®Google Scholar
• Ory-Magne F, Corvol JC, Azulay JP, et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 2014;82(4):300-7
   PubMed Web of Science ®Google Scholar
• Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007;130(Pt 7):1819-33
   PubMed Web of Science ®Google Scholar
• Munoz A, Li Q, Gardoni F, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008;131(Pt 12):3380-94
   PubMed Web of Science ®Google Scholar
• Kleedorfer B, Lees AJ, Stern GM. Buspirone in the treatment of levodopa induced dyskinesias. J Neurol Neurosurg Psychiatry 1991;54(4):376-7
   PubMed Web of Science ®Google Scholar
• Politis M, Wu K, Loane C, et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients. J Clin Invest 2014;124(3):1340-9
   PubMed Web of Science ®Google Scholar
• Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004;62(3):381-8
   PubMed Web of Science ®Google Scholar
• Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 2013;12(4):346-56
   PubMed Web of Science ®Google Scholar
• Ellenbogen A, Stocchi F, Duker A, et al. Comparison of single-dose motor effects of IPX066 to immediate-release carbidopa-levodopa+entacapone (CLE) in advanced Parkinson’s disease (PD) patients. (P361). Mov Disord 2012;27(Suppl):P361 Abstracts of the Sixteenth International Congress of Parkinson’s Disease and Movement Disorders
   Google Scholar
• Stocchi F, Dillmann U, Mahler A, et al. Comparison of IPX066, a novel investigational carbidopa-levodopa (CD-LD) extended-release formulation, and CD-LD-entacapone (CLE) in advanced Parkinson’s disease (ASCEND-PD trial). (P437). Mov Disord 2012;27(Suppl):P437 Abstracts of the Sixteenth International Congress of Parkinson’s Disease and Movement Disorders
   Google Scholar
• LeWitt P, Friedman H, Giladi N, et al. Sustained-release carbidopa-levodopa (accordion pill) in patients with advanced Parkinson’s disease: pharmacokinetic and clinical experience. [Abstract]. Mov Disord 2013;28(Suppl 1):499 Supplement: Abstracts of the Seventeenth International Congress of Parkinson’s Disease and Movement Disorders
   Google Scholar
• Depomed. Depomed Reports top line data for phase 2 study in Parkinson’s Disease. 2013. Available from: http://investor.depomedinc.com/phoenix.zhtml?c=97276&p=irol-newsArticle&ID=1755781&highlight
   Google Scholar
• A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson’s Disease Patients Receiving ND0612 (ND0612-003). Available from: http://clinicaltrials.gov/show/NCT01883505
   Google Scholar
• Efficacy and Safety Study of Inhaled CVT 301 in Parkinson’s Disease Patients for Treatment of OFF Episodes. Available from: http://clinicaltrials.gov/show/NCT01777555
   Google Scholar
• Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014;13(2):141-9
   PubMed Web of Science ®Google Scholar
• Mancini F, Comi C, Oggioni GD, et al. Prevalence and features of peripheral neuropathy in Parkinson’s disease patients under different therapeutic regimens. Parkinsonism Relat Disord 2014;20(1):27-31
   PubMed Web of Science ®Google Scholar
• Jugel C, Ehlen F, Taskin B, et al. Neuropathy in Parkinson’s disease patients with intestinal levodopa infusion versus oral drugs. PLoS One 2013;8(6):e66639
   PubMed Web of Science ®Google Scholar
• Lehnerer SM, Fietzek UM, Messner M, Ceballos-Baumann AO. Subacute peripheral neuropathy under duodopa therapy without cobalamin deficiency and despite supplementation. J Neural Transm 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Kuoppamaki M, Trenkwalder C, Vahteristo M, et al. Phase II proof of concept study to compare a novel levodopa product ODM-101 to levodopa/carbidopa/entacapone in Parkinson’s disease patients with response fluctuations (S23.005). Neurology 2013;80:S23.005 Meeting Abstracts
   Web of Science ®Google Scholar
• Efficacy and Safety Proof of Concept Study in Patients With Parkinson’s Disease and End-of-dose Motor Fluctuations (PARPOC). Available from: http://clinicaltrials.gov/show/NCT01766258
   Google Scholar
• CynapsusTherapeutics. Cynapsus announces positive results of CTH-104 clinical study of APL-130277 for Parkinson’s Disease. Press release. April 24, 2014 2014
   Google Scholar
• Phase IIa Multicentre Study Investigating of VR040 in Parkinson’s Disease (VR040/2/003). Available from: http://clinicaltrials.gov/show/NCT01693081
   Google Scholar
• Grosset KA, Malek N, Morgan F, Grosset DG. Inhaled apomorphine in patients with ’on-off’ fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study. J Parkinsons Dis 2013;3(1):31-7
   PubMedGoogle Scholar
• Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study). Available from: http://clinicaltrials.gov/show/NCT01397422
   Google Scholar
• Pahwa R, Tanner C, Hauser R, et al. Randomized trial of extended release amantadine in Parkinson’s disease patients with levodopa-induced dyskinesia (EASED study). Mov Disord 2013;28(Suppl):443 Abstracts of the Seventeenth International Congress of Parkinson’s Disease and Movement Disorders
   PubMedGoogle Scholar
• Bonifacio MJ, Sutcliffe JS, Torrao L, et al. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor. Neuropharmacology 2014;77:334-41
   PubMed Web of Science ®Google Scholar
• Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson’s Disease Patients. (BIPARKII). Available from: http://clinicaltrials.gov/show/NCT01227655
   Google Scholar
• Lees A, Ferreira JJ, Costa R, et al. Efficacy and safety of opicapone, a new COMT-inhibitor, for the treatment of motor fluctuations in Parkinson’s Disease patients: BIPARK-II study. J Neurol Sci 2013;333(Suppl 1):e116
   Google Scholar
• Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson’s Disease Patients With "Wearing-off" Phenomenon. Available from: http://clinicaltrials.gov/show/NCT01568073
   Google Scholar
• Rocha J, Falcao A, Pinto R, et al. Effect of opicapone and entacapone on levodopa pharmacokinetics when administered with immediate release 100/25 mg levodopa/carbidopa in healthy subjects. Mov Disord 2013;28: Supplement: Abstracts of the Seventeenth International Congress of Parkinson’s Disease and Movement Disorders
   Web of Science ®Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord 2014;29(2):229-37
   PubMed Web of Science ®Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord 2014;29(10):1273-80
   PubMed Web of Science ®Google Scholar
• Schapira A, Fox S, Hauser R, et al. Safinamide Add on to L-Dopa: A Randomized, Placebo-Controlled, 24-Week Global Trial in Patients with Parkinson’s Disease (PD) and Motor Fluctuations (SETTLE) (P01.062). Neurology 2013;80:P01.062 Meeting Abstracts 1
   Web of Science ®Google Scholar
• Barone P, Fernandez H, Ferreira J, et al. Safinamide as an Add-On Therapy to a Stable Dose of a Single Dopamine Agonist: Results from a Randomized, Placebo-Controlled, 24-Week Multicenter Trial in Early Idiopathic Parkinson Disease (PD) Patients (MOTION Study) (P01.061). Neurology 2013;80:P01.061 Meeting Abstracts 1
   Web of Science ®Google Scholar
• MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist. Available from: http://clinicaltrials.gov/show/NCT00605683
   Google Scholar
• Schapira AH, Stocchi F, Borgohain R, et al. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson’s disease. Eur J Neurol 2013;20(2):271-80
   PubMed Web of Science ®Google Scholar
• Pinna A. Adenosine A receptor antagonists in Parkinson’s disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs 2014;28(5):455-74
   PubMed Web of Science ®Google Scholar
• Schiffmann SN, Fisone G, Moresco R, et al. Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol 2007;83(5):277-92
   PubMed Web of Science ®Google Scholar
• Morelli M, Di Paolo T, Wardas J, et al. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog Neurobiol 2007;83(5):293-309
   PubMed Web of Science ®Google Scholar
• Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43(4):507-13
   PubMed Web of Science ®Google Scholar
• Bibbiani F, Oh JD, Petzer JP, et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease. Exp Neurol 2003;184(1):285-94
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Greeley DR, Zweig RM, et al. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat Disord 2010;16(1):16-20
   PubMed Web of Science ®Google Scholar
• Hauser RA. Future treatments for Parkinson’s disease: surfing the PD pipeline. Int J Neurosci 2011;121(Suppl 2):53-62
   PubMed Web of Science ®Google Scholar
• Chen W, Wang H, Wei H, Gu S. Istradefylline, an adenosine A(2)A receptor antagonist, for patients with Parkinson’s Disease: a meta-analysis. J Neurol Sci 2013;324(1-2):21-8
   PubMed Web of Science ®Google Scholar
• Tao Y, Liang G. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson’s disease: a meta-analysis of randomized controlled trials. Cell Biochem Biophys 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Mizuno Y, Kondo T. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease. Mov Disord 2013;28(8):1138-41
   PubMed Web of Science ®Google Scholar
• A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson’s Disease (KW-6002). Available from: http://clinicaltrials.gov/show/NCT01968031
   Google Scholar
• Perez-Lloret S, Merello M. Two new adenosine receptor antagonists for the treatment of Parkinson’s disease: istradefylline versus tozadenant. Expert Opin Pharmacother 2014;15(8):1097-107
   PubMed Web of Science ®Google Scholar
• Hauser RA, Olanow CW, Kieburtz KD, et al. Tozadenant (SYN115) in patients with Parkinson’s disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol 2014;13(8):767-76
   PubMed Web of Science ®Google Scholar
• Safety and Efficacy Study of SYN115 in Parkinson’s Patients Using Levodopa to Treat End of Dose Wearing Off. http://clinicaltrials.gov/show/NCT01283594
   Google Scholar
• Verhagen Metman L, Del Dotto P, Natte R, et al. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson’s disease. Neurology 1998;51(1):203-6
   PubMed Web of Science ®Google Scholar
• Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson’s Disease Patients (LID in PD). Available from: http://clinicaltrials.gov/show/NCT01767129
   Google Scholar
• Kobylecki C, Burn DJ, Kass-Iliyya L, et al. Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson’s disease. Parkinsonism Relat Disord 2014;20(4):452-5
   PubMed Web of Science ®Google Scholar
• Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson’s Disease (TOP-DYSK). Available from: http://clinicaltrials.gov/show/NCT01789047
   Google Scholar
• Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson’s Disease. Available from: http://clinicaltrials.gov/show/NCT00296959
   Google Scholar
• Steiniger B, Kretschmer BD. Effects of ibotenate pedunculopontine tegmental nucleus lesions on exploratory behaviour in the open field. Behav Brain Res 2004;151(1-2):17-23
   PubMed Web of Science ®Google Scholar
• Moreau C, Delval A, Tiffreau V, et al. Memantine for axial signs in Parkinson’s disease: a randomised, double-blind, placebo-controlled pilot study. J Neurol Neurosurg Psychiatry 2013;84(5):552-5
   PubMed Web of Science ®Google Scholar
• Samadi P, Gregoire L, Rouillard C, et al. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann Neurol 2006;59(2):282-8
   PubMed Web of Science ®Google Scholar
• Reducing Dyskinesia in Parkinson’s Disease With Omega-3 Fatty Acids (RLID-PD). Available from: http://clinicaltrials.gov/show/NCT01563913
   Google Scholar
• Balaban CD. Neural substrates linking balance control and anxiety. Physiol Behav 2002;77(4-5):469-75
   PubMed Web of Science ®Google Scholar
• Tohgi H, Abe T, Takahashi S. The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. J Neural Transm Park Dis Dement Sect 1993;5(1):27-34
   PubMedGoogle Scholar
• Fukada K, Endo T, Yokoe M, et al. L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson’s disease. Med Hypotheses 2013;80(2):209-12
   PubMed Web of Science ®Google Scholar
• Methylphenidate for the Treatment of Gait Impairment in Parkinson’s Disease. Available from: http://clinicaltrials.gov/show/NCT00526630
   Google Scholar
• Espay AJ, Dwivedi AK, Payne M, et al. Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial. Neurology 2011;76(14):1256-62
   PubMed Web of Science ®Google Scholar
• Moreau C, Delval A, Defebvre L, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson’s disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 2012;11(7):589-96
   PubMed Web of Science ®Google Scholar
• Stocchi F, Rascol O, Destee A, et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord 2013;28(13):1838-46
   PubMed Web of Science ®Google Scholar
• Berg D, Godau J, Trenkwalder C, et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 2011;26(7):1243-50
   PubMed Web of Science ®Google Scholar
• ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson’s Disease. Available from: http://clinicaltrials.gov/show/NCT01336088
   Google Scholar
• Tison F, Durif F, Corvol JC, et al. Safety, Tolerability and Anti-Dyskinetic Efficacy of Dipraglurant, a Novel mGluR5 Negative Allosteric Modulator (NAM) in Parkinson’s Disease (PD) Patients with Levodopa-Induced Dyskinesia (LID) (S23.004). Neurology 2013;80:S23.004 Meeting Abstracts 1
   Web of Science ®Google Scholar
• AddexTherapeutics. Dipraglurant. Press Release. 2014. Available from: www.addextherapeutics.com/rd/pipeline/dipra-ir/
   Google Scholar
• Novartis. Mavoglurant. Press Release. 2014. Available from: http://www.novartis.com/index.shtml
   Google Scholar
• Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia. Available from: http://clinicaltrials.gov/show/NCT00607451
   Google Scholar
• Lewitt PA, Hauser RA, Lu M, et al. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 2012;79(2):163-9
   PubMed Web of Science ®Google Scholar
• SantheraPharmaceuticals. Fipamezole for treatment of levodopa (L-dopa) induced Dyskinesia in Parkinson’s Disease; Expected USD 700m+ peak sales first-in-class opportunity for US and EU ready to enter Phase III. 2014. Available from: www.santhera.com/index.php?mid=4&vid=&lang=en
   Google Scholar
• Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson’s Disease. Available from: http://clinicaltrials.gov/show/NCT00623363
   Google Scholar
• Sage J, Hauser R, Cordon M, et al. Pilot study of the efficacy and safety of piclozotan in Parkinson’s disease patients with L-dopa induced motor complications. Abstract Mov Disord 2009;24(Suppl 1):S277
   PubMed Web of Science ®Google Scholar
• Quik M, Cox H, Parameswaran N, et al. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol 2007;62(6):588-96
   PubMed Web of Science ®Google Scholar
• Quik M, Mallela A, Ly J, Zhang D. Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson’s disease. Mov Disord 2013;28(10):1398-406
   PubMed Web of Science ®Google Scholar
• Xie CL, Pan JL, Zhang SF, et al. Effect of nicotine on L-dopa-induced dyskinesia in animal models of Parkinson’s disease: a systematic review and meta-analysis. Neurol Sci 2014;35(5):653-62
   PubMed Web of Science ®Google Scholar
• Study of NP002 in Subjects With Idiopathic Parkinson’s Disease to Treat Dyskinesias Due to Levodopa Therapy. Available from: http://clinicaltrials.gov/show/NCT00957918
   Google Scholar
• Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson’s Disease. Available from: http://clinicaltrials.gov/show/NCT01474421
   Google Scholar
• Zesiewicz TA, Greenstein PE, Sullivan KL, et al. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology 2012;78(8):545-50
   PubMed Web of Science ®Google Scholar
• Varenicline for Gait and Balance Impairment in Parkinson Disease (Chantix-PD). Available from: http://clinicaltrials.gov/show/NCT01341080
   Google Scholar
• Dyhring T, Nielsen EO, Sonesson C, et al. The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol 2010;628(1-3):19-26
   PubMed Web of Science ®Google Scholar
• Rung JP, Rung E, Helgeson L, et al. Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization. J Neural Transm 2008;115(6):899-908
   PubMed Web of Science ®Google Scholar
• Seeman P, Tokita K, Matsumoto M, et al. The dopaminergic stabilizer ASP2314/ACR16 selectively interacts with D2(High) receptors. Synapse 2009;63(10):930-4
   PubMed Web of Science ®Google Scholar
• Safety and Tolerability Study Evaluating ACR325 in Parkinson’s Disease Patients. Available from: http://clinicaltrials.gov/show/NCT01023282
   Google Scholar
• A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson’s Disease Subjects. Available from: http://clinicaltrials.gov/show/NCT01171313
   Google Scholar
• LeWitt PA, Huff FJ, Hauser RA, et al. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson’s disease. Mov Disord 2014;29(1):75-82
   PubMed Web of Science ®Google Scholar
• Lewitt PA, Ellenbogen A, Chen D, et al. Actively transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations. Clin Neuropharmacol 2012;35(3):103-10
   PubMed Web of Science ®Google Scholar
• A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson’s Disease Experiencing Motor Fluctuations and Dyskinesia. Available from: http://clinicaltrials.gov/show/NCT00903838
   Google Scholar
• Rascol O, Bronzova J, Hauser RA, et al. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism Relat Disord 2012;18(4):370-6
   PubMed Web of Science ®Google Scholar
• Mazzucchi S, Unti E, Del Prete E, et al. Can serotoninergic antidepressants prevent or delay the development of L-dopa induced dyskinesias in PD patients? Mov Disord 2013;28: Supplement: Abstracts of the Seventeenth International Congress of Parkinson’s Disease and Movement Disorders
   Web of Science ®Google Scholar
• MerckPharmaceuticals. Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine. 2013. Available from: www.mercknewsroom.com/press-release/research-and-development-news/merck-provides-update-phase-iii-clinical-program-prelade
   Google Scholar
• A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson’s Disease (P05664 AM5). Available from: http://clinicaltrials.gov/show/NCT01155479
   Google Scholar
• Stathis P, Konitsiotis S, Tagaris G, Peterson D. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson’s disease. Mov Disord 2011;26(2):264-70
   PubMed Web of Science ®Google Scholar
• Wong KK, Alty JE, Goy AG, et al. A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson’s disease. Mov Disord 2011;26(8):1552-5
   PubMed Web of Science ®Google Scholar
• Wolz M, Lohle M, Strecker K, et al. Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. J Neural Transm 2010;117(11):1279-86
   PubMed Web of Science ®Google Scholar
• Lyons KE, Pahwa R. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Clin Neuropharmacol 2006;29(3):148-53
   PubMed Web of Science ®Google Scholar
• Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson’s Disease Patients With Motor Fluctuations. Available from: http://clinicaltrials.gov/show/NCT00368108
   Google Scholar
• Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson’s Disease Subjects With Motor Fluctuations. Available from: http://clinicaltrials.gov/show/NCT00505622
   Google Scholar
• Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson’s Disease Patients With Motor Fluctuations. Available from: http://clinicaltrials.gov/show/NCT01634360
   Google Scholar
• Effects of Talampanel on Patients With Advanced Parkinson’s Disease. Available from: http://clinicaltrials.gov/show/NCT00036296
   Google Scholar
• Talampanel to Treat Parkinson’s Disease. Available from: http://clinicaltrials.gov/show/NCT00108667
   Google Scholar
• Lees A, Fahn S, Eggert KM, et al. Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson’s disease. Mov Disord 2012;27(2):284-8
   PubMed Web of Science ®Google Scholar
• Rascol O, Barone P, Behari M, et al. Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin Neuropharmacol 2012;35(1):15-20
   PubMed Web of Science ®Google Scholar
• Carbidopa-Levodopa Extended-Release (CD-LD ER) Alone or in Combination With Carbidopa-Levodopa Immediate Release (IR) to IPX066 Followed by Extension Safety Study of IPX066 in Subjects With Advanced Parkinson’s Disease. Available from: http://clinicaltrials.gov/show/NCT01411137
   Google Scholar
• Gastric Retentive Carbidopa/Levodopa in Parkinson’s Patients; a One Year, Open Label, Safety Extension Study. Available from: http://clinicaltrials.gov/show/NCT00947037
   Google Scholar
• Study in Advanced Parkinson’s Disease Patients With Predictable Motor Fluctuations. Available from: http://clinicaltrials.gov/show/NCT01515410
   Google Scholar
• Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson’s Subjects. Available from: http://clinicaltrials.gov/show/NCT00660387
   Google Scholar
• Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson’s Subjects. Available from: http://clinicaltrials.gov/show/NCT0357994
   Google Scholar
• A Study to Examine APL-130277 in Patients With Parkinson’s Disease Who Are Apomorphine Naïve. Available from: www.clinicaltrials.gov/show/NCT02228590
   Google Scholar
• Study of Memantine for Gait Disorders And Attention Deficit In Parkinson’s Disease (FOGG-I). Available from: http://clinicaltrials.gov/show/NCT01108029
   Google Scholar
• Augmenting Effects of L-DOPS With Carbidopa and Entacapone. Available from: http://clinicaltrials.gov/show/NCT00547911
   Google Scholar
• Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson’s Patients With L-dopa Induced Dyskinesias. Available from: http://clinicaltrials.gov/show/NCT01491932
   Google Scholar